Vero Biotech announced that it received FDA approval for its latest-generation tankless inhaled nitric oxide (iNO) delivery system.
Atlanta-based Vero Biotech developed its third-generation Genosyl delivery system for respiratory therapists. Its new features include faster dosing, simpler workflow and operational efficiency.
The system speeds up dosing with an adaptive sensor and automated cassette activation feature. These accelerate the time to achieve the desired dose. The company designed Genosyl so clinicians can work from one console. Each console includes a dual cassette bay that transitions cassettes automatically.
Finally, Vero Biotech improved the user interface and reduced the size and weight of its disposable cassettes. These improvements to operational efficiency alleviate storage constraints within hospitals, according to a news release.
“The enhancements to the Genosyl delivery system console will help me to work more efficiently,” said Denise Lauderbaugh, clinical practice specialist, Rady Children’s Hospital, San Diego.
Genosyl, the first tankless iNO delivery system approved by the FDA, dilates pulmonary blood vessels. This may help improve oxygenation in neonates with hypoxic respiratory failure and pulmonary hypertension. It generates iNO at the bedside with its small, disposable cassette.
“The continuous innovation of the Genosyl delivery system represents our commitment to neonatal intensive care and the acute care hospital community in providing solutions to the challenges they face,” said Brent V. Furse, CEO and president, Vero Biotech. “We are grateful for the partnership and support we received with the launch of our innovative tankless Genosyl delivery system and this collaboration that has and will allow Vero Biotech to continue to expand on its mission to save lives, alleviate suffering and improve the health economics of acute care.”